Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
20
CNSP Quote, Financials, Valuation and Earnings
Last price:
$6.03
Seasonality move
:
-48.4%
Day range:
$6.02 - $6.25
52-week range:
$4.93 - $114.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.38x
Volume:
46.7K
Avg. volume:
14.3K
1-year change:
-90.52%
Market cap:
$3.7M
Revenue:
--
EPS (TTM):
-$40.72
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CNSP
CNS Pharmaceuticals, Inc.
|
-- | -- | -- | -- | $20.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CNSP
CNS Pharmaceuticals, Inc.
|
$6.03 | $20.00 | $3.7M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
NNVC
NanoViricides, Inc.
|
$1.19 | $6.50 | $21.4M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.84 | $2.00 | $687.2K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CNSP
CNS Pharmaceuticals, Inc.
|
0.31% | 2.985 | 0.6% | 5.04x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CNSP
CNS Pharmaceuticals, Inc.
|
-$700 | -$3.3M | -147.68% | -150.13% | -- | -$2.2M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
CNS Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns CNSP or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to CNS Pharmaceuticals, Inc.'s net margin of -255.85%. CNS Pharmaceuticals, Inc.'s return on equity of -150.13% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital CNSPCNS Pharmaceuticals, Inc.-- -$5.76 $9.9M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About CNSP or NBY?
CNS Pharmaceuticals, Inc. has a consensus price target of $20.00, signalling upside risk potential of 221.03%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that CNS Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe CNS Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CNSPCNS Pharmaceuticals, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is CNSP or NBY More Risky?
CNS Pharmaceuticals, Inc. has a beta of 0.448, which suggesting that the stock is 55.222% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock CNSP or NBY?
CNS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. CNS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNSP or NBY?
CNS Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. CNS Pharmaceuticals, Inc.'s net income of -$3.2M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, CNS Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals, Inc. is -- versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNSPCNS Pharmaceuticals, Inc.-- -- -- -$3.2M NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns CNSP or NNVC?
NanoViricides, Inc. has a net margin of -- compared to CNS Pharmaceuticals, Inc.'s net margin of --. CNS Pharmaceuticals, Inc.'s return on equity of -150.13% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital CNSPCNS Pharmaceuticals, Inc.-- -$5.76 $9.9M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About CNSP or NNVC?
CNS Pharmaceuticals, Inc. has a consensus price target of $20.00, signalling upside risk potential of 221.03%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 446.22%. Given that NanoViricides, Inc. has higher upside potential than CNS Pharmaceuticals, Inc., analysts believe NanoViricides, Inc. is more attractive than CNS Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CNSPCNS Pharmaceuticals, Inc.0 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is CNSP or NNVC More Risky?
CNS Pharmaceuticals, Inc. has a beta of 0.448, which suggesting that the stock is 55.222% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock CNSP or NNVC?
CNS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CNS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNSP or NNVC?
CNS Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. CNS Pharmaceuticals, Inc.'s net income of -$3.2M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, CNS Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNSPCNS Pharmaceuticals, Inc.-- -- -- -$3.2M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns CNSP or OGEN?
Oragenics, Inc. has a net margin of -- compared to CNS Pharmaceuticals, Inc.'s net margin of --. CNS Pharmaceuticals, Inc.'s return on equity of -150.13% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital CNSPCNS Pharmaceuticals, Inc.-- -$5.76 $9.9M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About CNSP or OGEN?
CNS Pharmaceuticals, Inc. has a consensus price target of $20.00, signalling upside risk potential of 221.03%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 139.49%. Given that CNS Pharmaceuticals, Inc. has higher upside potential than Oragenics, Inc., analysts believe CNS Pharmaceuticals, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CNSPCNS Pharmaceuticals, Inc.0 0 0 OGENOragenics, Inc.1 0 0 -
Is CNSP or OGEN More Risky?
CNS Pharmaceuticals, Inc. has a beta of 0.448, which suggesting that the stock is 55.222% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock CNSP or OGEN?
CNS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CNS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNSP or OGEN?
CNS Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. CNS Pharmaceuticals, Inc.'s net income of -$3.2M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, CNS Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNSPCNS Pharmaceuticals, Inc.-- -- -- -$3.2M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns CNSP or PTN?
Palatin Technologies has a net margin of -- compared to CNS Pharmaceuticals, Inc.'s net margin of --. CNS Pharmaceuticals, Inc.'s return on equity of -150.13% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CNSPCNS Pharmaceuticals, Inc.-- -$5.76 $9.9M PTNPalatin Technologies-- -- -- -
What do Analysts Say About CNSP or PTN?
CNS Pharmaceuticals, Inc. has a consensus price target of $20.00, signalling upside risk potential of 221.03%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than CNS Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than CNS Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CNSPCNS Pharmaceuticals, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is CNSP or PTN More Risky?
CNS Pharmaceuticals, Inc. has a beta of 0.448, which suggesting that the stock is 55.222% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock CNSP or PTN?
CNS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CNS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNSP or PTN?
CNS Pharmaceuticals, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. CNS Pharmaceuticals, Inc.'s net income of -$3.2M is higher than Palatin Technologies's net income of --. Notably, CNS Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNSPCNS Pharmaceuticals, Inc.-- -- -- -$3.2M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns CNSP or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to CNS Pharmaceuticals, Inc.'s net margin of --. CNS Pharmaceuticals, Inc.'s return on equity of -150.13% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital CNSPCNS Pharmaceuticals, Inc.-- -$5.76 $9.9M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About CNSP or TOVX?
CNS Pharmaceuticals, Inc. has a consensus price target of $20.00, signalling upside risk potential of 221.03%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3497.12%. Given that Theriva Biologics, Inc. has higher upside potential than CNS Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than CNS Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CNSPCNS Pharmaceuticals, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is CNSP or TOVX More Risky?
CNS Pharmaceuticals, Inc. has a beta of 0.448, which suggesting that the stock is 55.222% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock CNSP or TOVX?
CNS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CNS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNSP or TOVX?
CNS Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. CNS Pharmaceuticals, Inc.'s net income of -$3.2M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, CNS Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNSPCNS Pharmaceuticals, Inc.-- -- -- -$3.2M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
